You are not logged in.

Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells

Tian, A, Wilson, GS, Lie, S, Wu, G, Hu, Z, Hebbard, L, Duan, W, George, J and Qiao, L 2014, Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells, Cancer Letters, vol. 351, no. 2, pp. 232-241, doi: 10.1016/j.canlet.2014.06.006.

Attached Files
Name Description MIMEType Size Downloads

Title Synergistic effects of IAP inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells
Author(s) Tian, A
Wilson, GS
Lie, S
Wu, G
Hu, Z
Hebbard, L
Duan, WORCID iD for Duan, W orcid.org/0000-0001-5782-9184
George, J
Qiao, L
Journal name Cancer Letters
Volume number 351
Issue number 2
Start page 232
End page 241
Total pages 10
Publisher Elsevier Ireland
Place of publication Shannon, County Clare, Ireland
Publication date 2014-09
ISSN 1872-7980
Keyword(s) Combinatorial therapy
Hepatocellular carcinoma
JAK signalling
LCL161
Paclitaxel
Science & Technology
Life Sciences & Biomedicine
Oncology
X-LINKED INHIBITOR
ANTIANGIOGENIC THERAPY
TARGETED THERAPIES
IN-VITRO
APOPTOSIS
CANCER
TUMOR
CARCINOGENESIS
BEVACIZUMAB
EXPRESSION
Summary Inhibitor of Apoptosis Proteins (IAPs) are key regulators of apoptosis in hepatocellular carcinoma (HCC) and their expression is negatively correlated with patient survival. LCL161 is a small molecule inhibitor of IAPs that has potent antitumour activity in a range of solid tumours. In HCC, response to LCL161 therapy has shown to be mediated by Bcl-2 expression. In this study, we aim to determine whether LCL161 has any therapeutic potential in HCC. Protein expression was determined by Western blot. Cell proliferation was determined by Cell Proliferation ELISA and BrdU colorimetric assays. Apoptosis was determined by Annexin V assay. Cell cycle analysis was performed by staining cells with propidium iodide and analysed in a FACScan. Automated Cell Counter and phase contrast microscopy were used to determine the cell viability. We have found that LCL161 targets (cIAP1, cIAP2 and XIAP) were up-regulated in HCC tumours. Both high Bcl-2 expressing HuH7 cells and low Bcl-2 expressing SNU423 cells showed strong resistance to LCL161 therapy with significant effects on both apoptosis and cell viability only evident at LCL161 concentrations of ⩾100μM. At these doses there was significant inhibition of IAP targets, however there was also significant inhibition of off-target proteins including pERK and pJNK suggesting apoptosis caused by drug toxicity. However, when used in combination with paclitaxel in HuH7 and SNU423 cells, LCL161 had significant antiproliferative effects at doses as low as 2μM and this was independent of Bcl-2 expression. Thus, LCL161 may be a useful agent in combination with paclitaxel to treat liver tumours.
Language eng
DOI 10.1016/j.canlet.2014.06.006
Field of Research 111299 Oncology and Carcinogenesis not elsewhere classified
Socio Economic Objective 920102 Cancer and Related Disorders
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2014, Elsevier
Persistent URL http://hdl.handle.net/10536/DRO/DU:30067324

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 13 times in TR Web of Science
Scopus Citation Count Cited 15 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 181 Abstract Views, 2 File Downloads  -  Detailed Statistics
Created: Mon, 08 Dec 2014, 12:34:40 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.